Living with vaccine-induced immune thrombocytopenia and thrombosis: a qualitative study.

Publication date: Jul 09, 2023

To explore the experiences of people up to 18 months after being diagnosed with vaccine-induced immune thrombocytopenia and thrombosis (VITT). A semistructured qualitative study, conducted via Zoom, of a cohort of people with VITT. Participants discussed their experiences of hospitalisation and following discharge. 14 individuals diagnosed with VITT, recruited via a Facebook support group and advertising on Twitter. Thematic analysis identified challenges of obtaining medical care and diagnosis; fear of the severity of symptoms and unclear prognosis; and lack of family support due to isolation imposed by the COVID-19 pandemic. Once home, participants experienced continued significant symptoms; fear of recurrence; inadequate medical knowledge of their condition; and difficulties coping with residual physical disabilities and psychosocial losses. Also reported were feelings of isolation and abandonment due to lack of government support. This is a significantly challenged group of people, with multiple health, financial, social and psychological losses. These losses have been compounded by experiences of limited governmental and societal recognition of the problems they face.

Open Access PDF

Concepts Keywords
Covid Bleeding disorders & coagulopathies
Facebook PSYCHIATRY
Fear PUBLIC HEALTH
Hospitalisation
Months

Semantics

Type Source Name
disease VO vaccine
disease MESH immune thrombocytopenia
disease MESH thrombosis
disease VO LACK
disease MESH COVID-19 pandemic
disease MESH infection
disease VO vaccination
disease VO effective
disease MESH backache
disease MESH chest pain
disease MESH deep vein thrombosis
disease MESH embolism
disease MESH seizures
disease MESH bleeding
disease MESH stroke
disease MESH dysphasia
disease MESH chronic headache
disease MESH myocardial infarction
disease MESH hypertension
drug DRUGBANK Trestolone
disease MESH syndrome
drug DRUGBANK Coenzyme M
disease VO protocol
disease VO population
disease IDO process
drug DRUGBANK Acetaminophen
disease IDO blood
disease MESH emergency
disease MESH death
disease MESH uncertainty
disease MESH panic
disease MESH long COVID
disease MESH migraine
disease MESH chronic fatigue syndrome
disease VO time
disease VO Thing
disease IDO symptom
disease MESH varices
disease MESH amnesia
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH lifestyle
disease MESH overinclusion
disease MESH sequelae
disease MESH mental disorders
pathway REACTOME Translation
disease MESH thrombocytopenia
disease MESH venous thromboembolism
disease MESH Postintensive care syndrome

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *